Price T Rowe Associates Inc Phathom Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 19,573 shares of PHAT stock, worth $200,623. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,573
Previous 17,401
12.48%
Holding current value
$200,623
Previous $159,000
30.82%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
54.7MCall Options Held
34KPut Options Held
58.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$104 Million5.64% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$76.5 Million20.79% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$35.8 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA3.16MShares$32.4 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$28.1 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $402M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...